Observational Study on Sars CoV2 Vaccinations in Patients with MS

• Conditions: En: MedDRA - 10084268En: MedDRA - 10084465; G35; U07.1; Multiple sclerosis; COVID-19, virus identified

• Registration Number: DRKS00025221
• Lead Sponsor: MS Forschungs- und Projektentwicklungs-gGmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-03
• Results First Posted: 2022-09-02
• Study Completion: 2023-04-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 3485

Inclusion Criteria

Multiple Sclerosis
Sars CoV2 Vaccination

Exclusion Criteria

Missing abillity to consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Online survey to capture the occourence of vaccination reactions in relation to basic data on the MS.<br>Surveys at time of 1st vaccination and at month 3, 6, and if needed 12.

Secondary Outcome Measures

Name	Time	Method
Relation between vaccination reactions and current / prior disease modifying therapy<br>Annualised Relapse rate changes and changes in MS progression in relation to the vaccination